LEADER 02531oam 2200673I 450 001 9910451554403321 005 20200520144314.0 010 $a1-134-90640-4 010 $a0-203-01027-2 010 $a1-280-19497-9 010 $a0-415-07351-0 024 7 $a10.4324/9780203010273 035 $a(CKB)1000000000442845 035 $a(SSID)ssj0000071110 035 $a(PQKBManifestationID)11107204 035 $a(PQKBTitleCode)TC0000071110 035 $a(PQKBWorkID)10071134 035 $a(PQKB)10929953 035 $a(MiAaPQ)EBC168929 035 $a(Au-PeEL)EBL168929 035 $a(CaPaEBR)ebr10054242 035 $a(CaONFJC)MIL19497 035 $a(OCoLC)50496752 035 $a(EXLCZ)991000000000442845 100 $a20180331d2000 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 10$aLiterary texts and the Greek historian /$fChristopher Pelling 210 1$aLondon ;$aNew York :$cRoutledge,$d2000. 215 $ax, 338 p 225 1 $aApproaching the ancient world 300 $aBibliographic Level Mode of Issuance: Monograph 311 $a0-415-07350-2 311 $a0-203-31167-1 320 $aIncludes bibliographical references (p. [306]-324) and indexes. 327 $a1. A culture of rhetoric -- 2. Rhetoric and history (415 BC) -- 3. How far would they go? Plutarch on Nicias and Alcibiades -- 4. Rhetoric and history II : Platnea (431-27 BC) -- 5. Explaining the war -- 6. Thucydides' speeches -- 7. 'You cannot be serious' : approaching Aristophanes -- 8. Aristophanes' Acharnians (425 BC) -- 9. Tragedy and ideology -- 10. Lysistrata and others : constructing gender -- 11. Conclusions : texts, audiences, truth. 410 0$aApproaching the ancient world. 606 $aGreek literature$xHistory and criticism 606 $aLiterature and history$zGreece$xHistory 606 $aHistory, Ancient$xHistoriography 606 $aHistoriography$zGreece$xHistory 607 $aGreece$xHistoriography 608 $aElectronic books. 615 0$aGreek literature$xHistory and criticism. 615 0$aLiterature and history$xHistory. 615 0$aHistory, Ancient$xHistoriography. 615 0$aHistoriography$xHistory. 676 $a880.9/0109358 700 $aPelling$b C. B. R.$0186663 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910451554403321 996 $aLiterary texts and the Greek Historian$9178458 997 $aUNINA LEADER 04062nam 22006014a 450 001 9910830297703321 005 20230828213302.0 010 $a1-280-54982-3 010 $a9786610549825 010 $a0-470-04340-7 010 $a0-470-04339-3 035 $a(CKB)1000000000355351 035 $a(EBL)270458 035 $a(OCoLC)476004231 035 $a(SSID)ssj0000159870 035 $a(PQKBManifestationID)11163367 035 $a(PQKBTitleCode)TC0000159870 035 $a(PQKBWorkID)10158686 035 $a(PQKB)11401578 035 $a(MiAaPQ)EBC270458 035 $a(EXLCZ)991000000000355351 100 $a20060516d2006 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aFundamentals of early clinical drug development$b[electronic resource] $efrom synthesis design to formulation /$fedited by Ahmed F. Abdel-Magid and Ste?phane Caron 210 $aHoboken, N.J. $cWiley-Interscience$dc2006 215 $a1 online resource (341 p.) 300 $aDescription based upon print version of record. 311 $a0-471-69278-6 320 $aIncludes bibliographical references and index. 327 $aReflections on process research II / Edward J.J. Grabowski -- Development and scale-up of a heterocyclic cross-coupling for the synthesis of 5-(2-(3-methyl-3H-imidazol-4-yl)thieno(3,2-b)pyridin-7-yl)amino-2-methyl-1H-indol / John A. Ragan -- Large-scale enantioselective preparation of 2E,7E, 5S,6R, 5-hydroxy-6-methyl-8-phenyl-octa-2,7-dienoic acid, a key fragment for the formal total synthesis of the anti-tumor agent cryptophycin 52 / James Aikins ... [et al.] -- Efforts toward a commercially viable route and process to the synthesis of HIV PI GW640385X / John C. Roberts ... [et al.] -- Development of an asymmetric synthesis of ABT-100 / Albert W. Kruger ... [et al.] -- Asymmetric hydrogenation: a new route to pregabalin / Rex Jennings ... [et al.] -- Responsibilities of the process chemist: beyond synthetic organic chemistry / Ste?phane Caron -- Outsourcing: the challenge of science, speed, and quality / Simone Andler-Burzlaff, Jason Bertola, and Roger E. Marti -- Automation and the changing face of process research in the pharmaceutical industry / Edward J. Delaney ... [et al.] -- Large scale synthesis: an engineering perspective / Joseph H. Childers, Jr. -- Synthesis and application of radioisotopes in pharmaceutical research and development / Larry E. Weaner and David C. Hoerr -- Selection of the drug form in exploratory development / George J. Quallich -- Strategies to control particle size of active pharmaceutical ingredients / David J. am Ende and Peter R. Rose -- Challenges in early formulation: turning drug substance into drug product / Mark H. Kleinman and Beeah Lee -- Intellectual property and early development / Maria I. Shchuka. 330 $aAn informative look at the intricacies of today's drug development processOnce a discovery organization has identified a potential new drug candidate, it is the daunting task of synthetic organic chemists to identify the chemical process suitable for preparation of this compound in a highly regulated environment. Only through a multi-layered chemical process that takes into account such factors as safety, environmental considerations, freedom to operate and cost-effectiveness can researchers begin to refine the drug in terms of quality and yield.This book covers both re 606 $aClinical pharmacology 606 $aPharmaceutical technology 606 $aDrugs$xTesting 615 0$aClinical pharmacology. 615 0$aPharmaceutical technology. 615 0$aDrugs$xTesting. 676 $a615.1 676 $a615.19 676 $a615/.1 701 $aAbdel-Magid$b Ahmed F.$f1947-$01613933 701 $aCaron$b Ste?phane$01613934 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910830297703321 996 $aFundamentals of early clinical drug development$93943490 997 $aUNINA